Status:
NO_LONGER_AVAILABLE
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
Lead Sponsor:
Provectus Biopharmaceuticals, Inc.
Conditions:
Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory
Approved Alternative Therapy
Eligibility:
All Genders
18+ years
Brief Summary
This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable ...
Eligibility Criteria
Inclusion
- Age 18 years or older, male or female.
- Histologically or cytologically confirmed cancer where there is no comparable or satisfactory approved alternative therapy specific to cutaneous or subcutaneous tumors.
- Performance Status: ECOG 0-2.
- Life Expectancy: At least 6 months.
- Blood Chemistry:
- Creatinine ≤ 3 times the upper limit of normal (ULN).
- Total bilirubin ≤ 3 times the upper limit of normal (ULN).
- AST/ALT/ALP ≤ 5 times the upper limit of normal (ULN).
- Thyroid Function
- Total T3 or free T3 (serum triiodothyronine), total T4 or free T4 (serum thyroxine) and THS (serum thyrotropin) ≤ grade 2 abnormality.
- Renal Function
- Subjects must have adequate renal function in the opinion of the Investigator with no clinically significant renal impairment or uncontrolled renal disease.
Exclusion
- Cancer patients who are eligible for an existing PV-10 clinical trial.
- Certain photosensitizing agents within 5 half-lives prior to PV-10 administration.
- Concurrent or Intercurrent Illness:
- Subjects with uncontrolled diabetes or extremity complications due to diabetes.
- Subjects with severe peripheral vascular disease.
- Subjects with significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise their safety or compliance or interfere with interpretation of study results.
- Subjects with uncontrolled thyroid disease, goiter, partial thyroidectomy, radioiodine- or surgically-treated Graves' hyperthyroidism or cystic fibrosis.
- Subjects with clinically significant acute or unstable cardiovascular, (stroke), renal, gastrointestinal, pulmonary, immunological (with the exception of the presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine, or central nervous system disorders.
- Pregnancy:
- Female subjects who are pregnant or lactating.
- Female subjects who have positive serum ßHCG pregnancy test taken within 7 days of PV-10 administration.
- Fertile subjects who are not using effective contraception.
- Investigational Agents:
- Subjects who have received investigational agents within 4 weeks (or 5 half-lives) of study administration.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01260779
Last Update
July 11 2016
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Louisville
Louisville, Kentucky, United States, 40202
2
St Luke's University Health Network
Bethlehem, Pennsylvania, United States, 18015
3
MD Anderson Cancer Center
Houston, Texas, United States, 77230
4
Melanoma Institute Australia
Sydney (North Sydney and Camperdown), New South Wales, Australia